Loading…
VivoSim Labs, INC.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.7% over 5Y.
today you would have $2.75▼ -99.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Year-end price | $0.22 | $1.81 | $5.52 | $13.32 | |
| P/S | 25.0x | 4.9x | 23.9x | 42.5x | 26.2x |
| P/B | 0.6x | — | 0.3x | 1.3x | 0.6x |
| EPS | -$5.35 | -$1.70 | -$19.25 | -$23.76 | |
| Profit margin | -7615.89% | -10567.18% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SPRCSciSparc Ltd. | $6.58 | 0.1x | 0.6x | — | -178.39% | $3.82M |
| ISPCiSpecimen Inc. | $1.54 | — | 0.1x | — | -968.47% | $3.88M |
| GOVXGeoVax Labs, Inc. | $0.72 | — | 3.0x | — | -891.59% | $3.76M |
| RDHLRedHill Biopharma Ltd. | $0.66 |
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and build functional 3D human tissues through its proprietary technologies that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Company description provided by Yahoo Finance.
| -1727.78% |
| -13459.63% |
| -4664.59% |
| ROE | -112.59% | — | -23.71% | -407.41% | -112.59% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.8x |
| — |
| — |
| $4.02M |
| RDGTRidgetech Inc. | $1.00 | — | 0.0x | — | -3.55% | $3.63M |
| SXTP60 Degrees Pharmaceuticals Inc | $1.03 | — | — | — | -332.85% | $3.62M |